• FortSumter
    Anybody following AFFY? Trying to determine if the PDFDA approval isa lready priced in.
    3/26/12
    Reply (12)
    • bigfoot: I wouldn't be surprised to see a spike tomorrow, but I think it is largely priced in.
      3/26/12
    • bigfoot: Long term, once they start posting revenues from peginesatide, I see this as a $30-$40 stock.
      3/26/12
    • bigfoot: (I started buying AFFY in 2010.)
      3/26/12
    • mystical44: I cant see how it is priced in given there is still a chance of rejection...
      3/26/12
    • bigfoot: well, we'll know for sure in about 27 hours.
      3/26/12
    • bigfoot: but review panel was 15-1 with one abstention in favor of approval.
      3/26/12
    • FortSumter: @bf - Seems like biotechs, even if they have the approval priced in, get some kind of bump. I'm holding and selling on the news. 2010 - wow!
      3/26/12
    • bigfoot: Yup, I'm currently up 80% in my position.
      3/26/12
    • bigfoot: I could see a short term spike up to about 16, settling back to 15 for the next few weeks.
      3/26/12
    • bigfoot: AFFY's next quarterly report is on May 5th, but I doubt peginesatide will be on the market by then.
      3/26/12
    • bigfoot: October may be the first time it has a big impact on revenues, unless there are more progress payments made by partners.
      3/26/12
    • FortSumter: Thanks for the info. My next watch is approval for VVUS. Jury is still out. Good arguments either way. Seems no brainer but then again.....
      3/26/12